ANI PHARMACEUTICALS INC (ANIP)
Health Care · Specialty pharmaceuticals and generic pharmaceutical manufacturing · NASDAQ
A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and strategic acquisitions.
What ANI PHARMACEUTICALS INC does
ANI Pharmaceuticals is a diversified bio-pharmaceutical company that develops, manufactures, and commercializes therapeutics across three segments: Rare Disease, Generics, and Brands. The company operates three pharmaceutical manufacturing facilities capable of producing oral solids, semi-solids, liquids, topicals, controlled substances, and potent products. Its portfolio includes over 120 generic products, branded therapies like Cortrophin Gel and ILUVIEN (for diabetic macular edema and non-infectious uveitis), and a robust pipeline expected to launch 10–15 new products annually.
Themes: Rare disease / specialty pharmaceuticals, Generic pharmaceuticals, Ophthalmology / retinal disease, Autoimmune disease treatment, Pharmaceutical manufacturing
Fundamentals
- Price$75.35 as of 2026-08-21 close
- Market cap$1.8B as of 2026-08-21
- 1-year return-17.3% 2025-08-21 close $91.14 → 2026-08-21 close $75.35
- P/E18.72 as of 2026-08-24
- Net margin+10.0% as of 2026-08-24
- Gross margin+60.8% as of 2026-08-24
- ROE+17.8% as of 2026-08-24
- Debt / equity1.09 as of 2026-08-24
- Revenue growth (YoY)+37.0% as of 2026-08-24
- Revenue CAGR (3y)+40.8% SEC XBRL
- Beta0.51 as of 2026-08-24
- Last reported earnings2026-08-07 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.0%; pays a dividend.
How ANIP compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- indicated dividend yieldbottom 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, ANIP's dividend was covered by reported results (earnings payout 1%, free-cash-flow payout 1%). This describes past coverage, not a forecast.
- Earnings payout1% dividends / net income
- Free-cash-flow payout1% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How ANI PHARMACEUTICALS INC looks technically
ANI PHARMACEUTICALS INC (ANIP) is trading 6.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day low about 9 trading days ago. It is 24.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.1% below its 200-day average, the long-term trend line — a long-term downtrend | -6.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $80.27 | $80.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $80.29 | $80.29 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 73.27. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal | 1 session |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($73.27 to $83.21) — its "stochastic" reading is 21 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 20.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $99.50 | $99.50 |
|---|---|---|
| From the 52-week high | it is 24.3% below its 52-week high (its highest price of the past year) | -24.3% |
| Above the 52-week low | it is 7.4% above its 52-week low (its lowest price of the past year) | +7.4% |
| Below the 52-week high | it is 24.3% below its highest point of the past year | 24.3% |
| Since a 20-day breakout | it made a new 20-day low about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $286.85 (set on 2007-05-09) | $286.85 |
| Given back of the 52-week move | over the past year its closes ranged ($70.49 to $98.81), and it has recovered roughly a quarter of its fall from last year’s high — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $87.99 to $88.90. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.2% |
| From the all-time high | it is 73.7% below its all-time high | -73.7% |
| Nearest price level | it is trading 1.0% below a resistance level at $76.09 — a price it turned at 7 times since 2025-05-09, most recently on 2026-07-23. Since 2024-08-21 it has 9 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $4.79 (set on 2013-06-26) | $4.79 |
| Above the all-time low | it is 1472.7% above its all-time low | +1,473% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 78% of it) | 78th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.60 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.60 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $73.31 and $82.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $73.31 – $78.06 – $82.80 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 1.9 daily ranges below its 200-day average price (6.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.14× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.5% since the prior reading | -1.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|---|---|
| Open gap | it gapped 6.8% below the previous close 10 sessions ago and has not traded back through the level it left behind at 82.63 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.8% |
| Gap filled | a 2.4% gap up opened on 2026-06-11 has been "filled" 45 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 45 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.42% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.1 percentage points (the stock lost 4.8% while the market gained 2.3%) | -7.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 12.1 percentage points (the stock lost 9.0% while the market gained 3.1%) | -12.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.2 percentage points (the stock lost 3.1% while the market gained 11.1%) | -14.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 37.8 percentage points (the stock lost 17.3% while the market gained 20.5%) | -37.8% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.5% of the share price. | -6.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $79.31 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | -5.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-07 (its 10-Q), so the typical buyer over that stretch is under water. That average is $76.35 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | -1.3% |
Price levels it has turned at before
ANIP last closed at $75.35 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $76.09 | Resistance | 1.0% above the last close | turned there 7 times · 2025-05-09 to 2026-07-23 |
| $72.97 | Support | 3.2% below the last close | turned there four times · 2026-02-27 to 2026-08-12 |
| $78.14 | Resistance | 3.7% above the last close | turned there five times · 2025-11-21 to 2026-06-18 |
| $79.69 | Resistance | 5.8% above the last close | turned there twice · 2025-11-07 to 2025-12-12 |
| $69.03 | Support | 8.4% below the last close | turned there twice · 2025-04-02 to 2025-07-18 |
| $67.19 | Support | 10.8% below the last close | turned there twice · 2025-06-24 to 2025-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $73.27.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $76.42.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$108.38 range $90.00 – $121.00; median $109.50
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ANIP
- Consensus EPS estimate$2.20 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant competition and rapidly changing market environment; success of competing therapies may impact product acceptance and pricing power","Manufacturing and regulatory compliance risks across three operating facilities; reliance on third-party suppliers for critical raw materials and contract manufacturing services","Integration risks and debt burden from Alimera acquisition ($325M term loan and $316.25M convertible notes due 2029) may impact financial flexibility and profitability"]
What changed in the latest 10-Q
AI-assisted comparison of ANIP's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08): Added statement that 'During 2026, we are building a dedicated sales organization focused on acute gouty arthritis flares, an indication unique to Cortrophin Gel within the ACTH class.'
- Newer filing (2026-05-08): Added clarification that the Company 'owns and operates' three pharmaceutical manufacturing facilities (versus older language stating they 'are together capable').
- Newer filing (2026-05-08): Reference to 2025 Form 10-K instead of 2024 Form 10-K.
- Removed:
- Older filing (2025-11-07): Removed detailed statement 'The acquisition of Alimera is anticipated to strengthen our Rare Disease business' and replaced with 'strengthened' (past tense).
- Older filing (2025-11-07): Removed language 'ANI sees the potential to unlock significant additional growth for the Retina Franchise through commercial synergies and execution.'
- Older filing (2025-11-07): Removed detailed description of manufacturing partnerships: 'In order to support the transition to ILUVIEN, in July 2024, the Company extended its partnership with Alliance Medical Products, Inc., a subsidiary of Siegfried Holding AG ("Siegfried"), its long-term supplier for ILUVIEN, through 2029, and contracted with Siegfried to upgrade equipment on the existing manufacturing line and significantly expand capacity through the addition of a second manufacturing line.'
- Older filing (2025-11-07): Removed statement that 'ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.'
- Reworded:
- Older 'establishing and expanding' changed to 'expanding' in newer filing (2026-05-08).
- Older 'acquisition' changed to 'acquisitions' (plural) in newer filing discussing future strategy (2026-05-08).
- Older 'In September 2024, we acquired ILUVIEN and YUTIQ (the "Retina Franchise")' changed to 'In September 2024, we acquired ILUVIEN and YUTIQ (together, the "Retina Franchise")' in newer filing (2026-05-08).
- Older 'Our three pharmaceutical manufacturing facilities' changed to 'The Company owns and operates three pharmaceutical manufacturing facilities' in newer filing (2026-05-08).
- Older 'refer below for further information related to the expanded label' reference removed in newer filing (2026-05-08).
- Older 'is anticipated to strengthen' changed to 'strengthened' (past tense, indicating completed action) in newer filing (2026-05-08).
- Older 'ANI' full name reference changed to simpler structure in newer filing (2026-05-08).
- Notes:
- The newer filing's MD&A section appears truncated at the end ('Our most recent business acquisition in the Generics and Other segment was the acquisition of Novitium Pharma LLC...' followed by incomplete text), limiting full comparison of the Generics section.
- The older filing's MD&A section is also truncated ('Additionally, on February 28, 2025...' and 'which remains availab'), affecting complete assessment of later sections.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($513090) — 3 selling insiders
- Last 90 days0 buys · 9 sells ($2M) — 4 selling insiders
- Last 180 days0 buys · 16 sells ($7M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ANIP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ANIP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,845,740
- Reported value $295,737,412
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ANIP had 2,334,112 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for ANIP because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 2,334,112
- Prior settlement (shares) 3,371,249
- Reported change -30.76%
- Days to cover (reported) 9.25
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teva Pharmaceutical Industries
- Mallinckrodt Pharmaceuticals
- Bausch + Lomb (eye care and ophthalmology)
- Allergan (now AbbVie specialty care)
- Sun Pharmaceutical
- Apotex
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does ANI PHARMACEUTICALS INC (ANIP) do?
ANI Pharmaceuticals is a diversified bio-pharmaceutical company that develops, manufactures, and commercializes therapeutics across three segments: Rare Disease, Generics, and Brands. The company operates three pharmaceutical manufacturing facilities capable of producing oral solids, semi-solids, liquids, topicals, controlled substances, and potent products.
What sector is ANI PHARMACEUTICALS INC (ANIP) in?
ANI PHARMACEUTICALS INC (ANIP) is classified in the Health Care sector. Its industry is Specialty pharmaceuticals and generic pharmaceutical manufacturing. It trades on NASDAQ.
Does ANIP pay a dividend?
Yes — ANI PHARMACEUTICALS INC (ANIP) pays a dividend, with an indicated yield of about 0.04% (market data, as of 2026-08-24). Informational only — not financial advice.
Who are ANI PHARMACEUTICALS INC's (ANIP) competitors?
Notable peers of ANI PHARMACEUTICALS INC (ANIP) include Teva Pharmaceutical Industries, Mallinckrodt Pharmaceuticals, Bausch + Lomb (eye care and ophthalmology), Allergan (now AbbVie specialty care) and Sun Pharmaceutical. This peer set is informational only — not financial advice.
Is ANI PHARMACEUTICALS INC (ANIP) overbought or oversold right now?
ANI PHARMACEUTICALS INC (ANIP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ANIP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.